Henagliflozin/metformin/retagliptin (Shandong Shengdi)

ๆ’ๆ ผๅˆ—ๅ‡€็‘žๆ ผๅˆ—ๆฑ€ไบŒ็”ฒๅŒ่ƒ็ผ“้‡Š็‰‡(ๅฑฑไธœ็››่ฟช)

Report date: 2025/12/09 11:38:54

Base Information

Drug NameHenagliflozin/metformin/retagliptin (Shandong Shengdi)
Drug Alias Nameๆ’ๆ ผๅˆ—ๅ‡€็‘žๆ ผๅˆ—ๆฑ€ไบŒ็”ฒๅŒ่ƒ็ผ“้‡Š็‰‡๏ผˆโ… ๏ผ‰ๆ’ๆ ผๅˆ—ๅ‡€็‘žๆ ผๅˆ—ๆฑ€ไบŒ็”ฒๅŒ่ƒ็ผ“้‡Š็‰‡๏ผˆโ…ก๏ผ‰็‘žไนๅ”HR20031HR-20031
ClassificationSmall molecules
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsDipeptidyl peptidase IVSodium/glucose cotransporter 2Protein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus, Type 2Diabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2025/10/21
Country/TerritoryMainland China
CombinationsYes Henagliflozin ProlineMetformin HydrochlorideRetagliptin Phosphate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShandong Shengdi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Shengdi Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A